105512-79-6Relevant articles and documents
Aminothiazole-featured pirinixic acid derivatives as dual 5-lipoxygenase and microsomal prostaglandin E2 synthase-1 inhibitors with improved potency and efficiency in vivo
Hanke, Thomas,Dehm, Friederike,Liening, Stefanie,Popella, Sven-Desiderius,MacZewsky, Jonas,Pillong, Max,Kunze, Jens,Weinigel, Christina,Barz, Dagmar,Kaiser, Astrid,Wurglics, Mario,L?mmerhofer, Michael,Schneider, Gisbert,Sautebin, Lidia,Schubert-Zsilavecz, Manfred,Werz, Oliver
, p. 9031 - 9044 (2013)
Dual inhibition of microsomal prostaglandin E2 synthase-1 (mPGES-1) and 5-lipoxygenase (5-LO) is currently pursued as potential pharmacological strategy for treatment of inflammation and cancer. Here we present a series of 26 novel 2-aminothiaz
Design, synthesis, docking studies and biological screening of 2-thiazolyl substituted -2,3-dihydro-1H-naphtho[1,2-e][1,3]oxazines as potent HIV-1 reverse transcriptase inhibitors
Gawali, Rakhi,Trivedi, Jay,Bhansali, Sujit,Bhosale, Raghunath,Sarkar, Dhiman,Mitra, Debashis
, p. 310 - 319 (2018)
1,3-oxazine nucleus and thiazolyl group features prominently in many biologically important natural products as well as bioactive molecules. A series of novel 2-thiazolyl substituted-2,3-dihydro-1H-naphtho [1,2-e][1,3]oxazine derivatives were designed and
Based on isoxazole substitution of benzamide derivatives and anti-prostate cancer drug applications
-
Paragraph 0065; 0073-0074, (2022/01/10)
The present invention discloses a class (I), formula (II) structure based on isoxazole substituted benzamide derivatives and antiprostate cancer drug applications, such isoxazole substituted benzamide derivatives, can effectively inhibit the activity of a
Structure-Based Design of N-(5-Phenylthiazol-2-yl)acrylamides as Novel and Potent Glutathione S-Transferase Omega 1 Inhibitors
Dai, Weiyang,Samanta, Soma,Xue, Ding,Petrunak, Elyse M.,Stuckey, Jeanne A.,Han, Yanyan,Sun, Duxin,Wu, Yong,Neamati, Nouri
, p. 3068 - 3087 (2019/03/07)
Using reported glutathione S-transferase omega 1 (GSTO1-1) cocrystal structures, we designed and synthesized acrylamide-containing compounds that covalently bind to Cys32 on the catalytic site. Starting from a thiazole derivative 10 (GSTO1-1 IC50 = 0.6 μM), compound 18 was synthesized and cocrystallized with GSTO1. Modification on the amide moiety of hit compound 10 significantly increased the GSTO1-1 inhibitory potency. We solved the cocrystal structures of new derivatives, 37 and 44, bearing an amide side chain bound to GSTO1. These new structures showed a reorientation of the phenyl thiazole core of inhibitors, 37 and 44, when compared to 18. Guided by the cocrystal structure of GSTO1:44, analogue 49 was designed, resulting in the most potent GSTO1-1 inhibitor (IC50 = 0.22 ± 0.02 nM) known to date. We believe that our data will form the basis for future studies of developing GSTO1-1 as a new drug target for cancer therapy.
Method for performing driving synthesis of 4-alkyl or aryl-2-aminothiazole by visible light
-
Paragraph 0063; 0064; 0065; 0066; 0067; 0068, (2018/04/02)
The invention relates to a method for performing driving synthesis of 4-alkyl or aryl-2-aminothiazole by visible light. The method comprises the following steps: adding an olefin azide compound, ammonium thiocyanate and copper acetate into a solvent acetonitrile separately, performing driving reaction by using visible light with wavelength of 450 to 460 nm at the temperature of 25 DEG C for 20 to36 hours to obtain reaction liquid, and spin-drying the reaction liquid to obtain concentrate; and performing silica-gel column chromatography on the concentrate to obtain the 4-alkyl or aryl-2-aminothiazole. The method is high in yield, mild in condition and low in environmental pollution.
